阿德福韦酯对不同基因型乙型肝炎的疗效分析

Clinical analysis of adefovir dipivoxil for different genotype of HBV

目的:探讨阿德福韦酯对不同基因型乙型肝炎的临床疗效。方法:选取2006年9月～2009年9月于就诊的乙型肝炎患者183例。所有患者均用阿德福韦酯治疗,10mg/d,连用48周。治疗前取各个患者1.5mL静脉血并提取DNA,PCR扩增HBV DNA,根据DNA长度分析患者的基因型。结果:患者为B基因型98例,C基因型75例;B+C基因型10例。治疗12周、24周、36周和48周时,B型、C型和B+C型患者ALT、HBV的DNA下降比例超过2log10和完全抑制HBV DNA的情况差异均无统计学意义(均P>0.05)。结论:阿德福韦酯对B型、C型和B+C型的乙型肝炎具有相同的治疗效果。

Objective： To investigate the clinical effects of adefovir dipivoxil on different genotype of HBV.Methods： A total of 183 HBV patients who received adefovir dipivoxil treatment in our hospital from Sep.2006 to Sep.2009 were enrolled in this research.All the patients received adefovir dipivoxil 10 mg per day and last for 48 weeks.1.5 mL venous blood was taken from all the patients for DNA extraction before treatment.PCR amplified HBV DNA and then classified the genotype according to the DNA length.Results： Ninety-eight patients were type B and 75 patients were type C,while 10 patients were type B plus C.At 12,24,36 and 48 weeks,serum ALT level,HBV DNA decreased more than 2log10 and completely inhibition of the three genotypes had no significant difference.Conclusion： Adefovir dipivoxil has the same clinical effect for different HBV genotypes.